



Memo

Date:

January 31, 2022

To: Primary care providers

From: Brian Ktytor, Chief Regional Officer, North
Anna Greenberg, Chief Regional Officer, Toronto and East
Susan deRyk, Chief Regional Officer, Central and West

CC: Mark Walton, Senior Vice President, COVID-19 Pandemic Response, Ontario Health

Dr. Sacha Bhatia, Population Health and Value Based Health Systems Executive, Ontario Health

Patrick Dicerni, Assistant Deputy Minister, OHIP, Pharmaceuticals and Devices Division, Ministry of Health

Nadia Surani, Director, Primary Health Care Branch, Ministry of Health

Re: Access to outpatient therapies for COVID-19 (sotrovimab and Paxlovid)

On January 17, 2022, the oral antiviral Paxlovid was approved by Health Canada for eligible adults with COVID-19. The Ontario COVID-19 Science Advisory Table has released updated guidance that incorporates Paxlovid in their [recommendations for therapeutic management of adult patients with COVID-19](#). The recommendations also include sotrovimab, a monoclonal antibody.

The supply is currently limited for these two options for outpatient therapy in Canada. Ontario is distributing these therapeutics through a limited number of sites across the province and prioritizing individuals who are at higher risk for severe outcomes from COVID-19 infection. Primary care providers will be instrumental in the early identification of patients who could benefit from access to these treatments and in referring their eligible patients to the sites offering the therapeutics.

This package is intended to provide key information for primary care providers on how to access sotrovimab and Paxlovid for eligible patients. It includes the following:

- Guidance for primary care providers on how to access sotrovimab and Paxlovid
- A common referral form for monoclonal therapy clinics that administer sotrovimab
- A list of sites distributing Paxlovid and information on referral to these sites

Given the limited supply of these therapeutics, Ontario Health and the Ministry of Health will be monitoring usage and supply of these medications very closely. As supply increases, eligibility may be expanded in order to ensure that those populations in most need of treatment have access.

Thank you for your attention to this information and for your ongoing dedication to providing the best possible care for your patients.